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Abstract This article, based on original data as well as on
previously reported preclinical and clinical data that are
reviewed, describes direct and indirect interactions of the
D3 receptor with N-methyl-D-aspartate receptor (NMDA)
signaling and their functional consequences and therapeutic
implications for schizophrenia. D3 receptor immunoreactiv-
ity at ultrastructural level with electron microscopy was
identified at presumably glutamatergic, asymmetric synap-
ses of the medium-sized spiny neurons of the nucleus
accumbens. This finding supports the existence of a direct
interaction of the D3 receptor with glutamate, in line with
previously described interactions with NMDA signaling
involving Ca2+/calmodulin-dependent protein kinase II at
post-synaptic densities (Liu et al. 2009). Indirect interac-
tions of the D3 receptor with glutamate could involve a
negative control exerted by the D3 receptor on mesocortical
dopamine neurons and the complex regulation of the gluta-
matergic pyramidal cells by dopamine in the prefrontal
cortex. This could be exemplified here by the regulation of
pyramidal cell activity in conditions of chronic NMDA
receptor blockade with dizocilpine (MK-801). BP897, a
D3 receptor-selective partial agonist, reversed the dysregu-
lation of cortical c-fos mRNA expression and pyramidal cell
hyperexcitability, as measured by paired-pulse electrophys-
iology. At the behavioral level, blockade of the D3 receptor,
by known D3 receptor antagonists or the novel D3 receptor-
selective antagonist F17141, produces antipsychotic-like
effects in reversing hyperactivity and social interaction def-
icits induced by NMDA receptor blockade by MK-801 in
mice. The glutamate–D3 receptor interactions described here
offer a conceptual framework for developing new D3
receptor-selective drugs, which may appear as an original,
efficacious, and safe way to potentially indirectly target
glutamate in schizophrenia.
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Introduction
Since its discovery (Sokoloff et al. 1990), much progress
has been accomplished toward understanding the physiolog-
ical role of the dopamine D3 receptor and defining the
potential indications of pharmacological drugs specifically
acting on this receptor. At the anatomical level, the brain
regions where the D3 receptor is expressed have been
delineated, and the phenotypes of D3 receptor-expressing
neurons have been characterized (Bouthenet et al. 1991;
Diaz et al. 1995). These studies underscore the limited
and restricted distribution of the D3 receptor in the brain,
seemingly related to functions of dopamine associated
with the limbic brain. Hence, the hypothesis has been
put forward that the D3 receptor could be involved in the
pathophysiology of several psychiatric disorders, which
result from dysfunction of dopamine neurotransmission
(Sokoloff et al. 2006).
Several review articles published during the last decade,
as well as earlier and recent original research articles, have
been published to support this hypothesis. Nowadays, com-
pelling evidence from preclinical and genetic studies exists
to implicate the D3 receptor in three major pathological
domains, namely, drug addiction, movement disorders, and
schizophrenia, even though only little clinical results came
in support. In this respect, a major advance has been accom-
plished with the discovery and use of D3 receptor-selective
pharmacological drugs. Starting with the phenylpiperazine
derivative BP 897 (Pilla et al. 1999), a number of original
compounds, yet with structural similarities, were designed
(Micheli and Heidbreder 2006; Boeckler and Gmeiner
2006), and a patent survey indicates that, since 2005, 110
patents or patent applications have been published, which
shows that this is still a very active research area, in both
academic and industrial laboratories. In these patents, a
number of indications are targeted by D3 receptor-selective
drugs. However, those for which the rationale is supported
by compelling data are more limited, and they will be
briefly reviewed here; the reader is also invited to refer
to accompanying articles of this special issue for an
updated information.
Drug addiction remains one of the first indications for D3
receptor partial agonists and antagonists. Following the
discovery of the role of D3 receptor in cocaine self-
administration (Caine and Koob 1993) and in cue-induced
cocaine-seeking behavior (Pilla et al. 1999), numerous stud-
ies have investigated D3 receptor drugs in animal models of
addiction to various abused drugs, including psychostimu-
lants, opioids, nicotine, and alcohol. The preclinical evi-
dence indicates that the D3 receptor antagonism diminishes
motivation to self-administer drugs, in particular in condi-
tions of high price for drugs, and disrupts drug-associated
cue-induced craving and stress-induced reinstatement
(Heidbreder et al. 2005; Heidbreder and Newman 2010;
Le Foll et al. 2005; 2007). The modulation by the D3
receptor of the effects of food-associated cues on over-
weight and obese patients has recently been demonstrated
in a clinical study (Nathan et al. 2012).
Movement disorders include several conditions, of which
a detectable increased risk could be associated with the
presence of the Gly allele of DRD3 polymorphism, which
showed an increased function in vitro compared to the Ser
allele (Jeanneteau et al. 2006). The movement disorders
include tardive dyskinesia (Lerer et al. 2002), a debilitating
and stigmatizing condition emerging after long-term treat-
ment with antipsychotics and essential tremor (Jeanneteau et
al. 2006), a slowly progressive disorder most frequently
characterized by an action (kinetic or postural) tremor of
the arms and hands. Restless legs syndrome involves abnor-
mal limb sensations that diminish with motor activity and
exacerbate at night. It has been associated with the D3
receptor, on the basis that the therapeutic agents for this
condition are D3-preferential agonists. Additionally, D3
receptor-deficient mice exhibit facilitation rather than the
expected depression of spinal reflexes in the presence of
dopamine (Clemens et al. 2006) and also resemble a mouse
model of restless legs syndrome, with respect to sensory and
motor symptoms (Dowling et al. 2011). Dyskinesia in
Parkinson’s disease consists of intractable and pharmacor-
esistant involuntary movements resulting to sensitization to
substitution treatment, particularly L-DOPA, and has been
associated in rat (Bordet et al. 1997) and monkey (Bezard et
al. 2003) models with an increased D3 receptor expression
and function (see also Visanji et al. 2006).
The rationale of using D3 receptor antagonists in the
treatment of schizophrenia mainly arises from the observa-
tion that all registered antipsychotic drugs bind with almost
equal affinities to D2 and D3 receptors in vitro (Sokoloff et
al. 1992; Malmberg and Mohell 1995). Whether these drugs
actually bind to cerebral D3 receptors at therapeutically
active doses has been a matter of controversy. In a positron
emission tomography (PET) study in patients with schizo-
phrenia, atypical antipsychotics failed to occupy D3 recep-
tors in the D3-rich brain regions globus pallidus and
substantia nigra (Graff-Guerrero et al. 2009a; Mizrahi et
al. 2011). However, a PET study in non-human primates
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issued from another laboratory (Girgis et al. 2011) provided
evidence that acute therapeutically active doses of clozapine
and haloperidol readily bind to D3 receptors in vivo and that
the discrepancies with the former studies can be accounted
by methodological considerations. Besides this pharmaco-
logical evidence, there are also compelling data, which will
be reviewed in detail below, showing that the D3 receptor is
localized at positions in neurons critical for controlling
psychotic symptoms and that preclinical models of schizo-
phrenia reveal the antipsychotic-like properties of D3 recep-
tor antagonists, of which one original compound will be
described.
Our major aims in this article will be to extract from the
above literature, to present novel experimental evidence,
and to discuss the hypothesis that the physiological role of
the D3 receptor in schizophrenia may actually be underlined
by direct and indirect interactions of this receptor with
glutamate pathways. This hypothesis is consistent with the
idea that schizophrenia results from both dopamine and
glutamate dysfunctions and from dopamine–glutamate im-
balance (Carlsson 1988; Goff and Coyle 2001; Javitt 2004).
It may also offer a theoretical frame for the use of D3
antagonists in the treatment of schizophrenia, as a therapeu-
tic alternative to direct glutamatergic antipsychotic drugs,
such as agonists or positive modulators of the metabotropic
glutamate receptor subtypes 2 and 3 (mGluR2/3) (Patil et al.
2007) and inhibitors of type 1 glutamate uptake (Alberati et
al. 2012), which are presently promising treatments, but,




(+)-Dizocilpine maleate (MK-801, Sigma), BP 897 (dihy-
drochloride salt, Bioprojet), and F17141 (hydrochloride salt,
synthesized at Pierre Fabre Research Institute) were dis-
solved in sterile water. All solutions will be prepared fresh
daily and injected in a volume of 10 mlkg-1. Doses are
expressed in milligram per kilogram of the free base.
Animals
For immunochemistry, rats were anesthetized deeply with
sodium pentobarbital and then perfused transcardially with
saline solution (50 ml of 0.9 % NaCl warmed at 37 °C),
followed by 600 ml of an ice-cooled fixative solution
containing 3 % paraformaldehyde in 0.1 M phosphate
buffer, pH 7.4, or containing 3 % paraformaldehyde,
0.1 % glutaraldehyde, 0.2 % picric acid in 0.1 MPB, pH
7.4, for immunoelectron microscopy. The brains were
removed and post-fixed for 2 h at 4 °C in the same fixative
used for perfusion. Brains were cut with a vibratome in
coronal sections of 40 μm that were cryoprotected in
0.1 M phosphate buffer, pH 7.4, containing 30 % sucrose
and freeze-thawed (−75 °C) before use for immunostaining.
For behavioral studies, male Swiss mice Crl:OF1 (IFFA
CREDO, France), weighting 20–22 g upon arrival, were
housed five to eight per cage with sawdust bedding (poly-
carbonate type III cages; L 375 mm, l 215 mm, H 149 mm;
floor surface 806 cm2), on a 12-/12-h light/dark cycle (lights
on at 07:00 a.m.), with food and water freely available.
Room temperature ranged from 20 to 22 °C, and humidity
varied between 55 and 65 %. In the resident intruder test,
half of the mice were single-housed (Cristal PS cages , L
220 mm, 85 mm, H 80 mm; floor surface 187 cm2) until the
end of the experiment (see below).
Immunohistochemistry
For double-immunofluorescent labeling, cryostat sections
(10 μm) of rat brain nucleus accumbens were blocked for
1 h at room temperature in 0.05 M Tris-buffered saline
(TBS), pH 7.4, containing 5 % donkey normal serum,
0.4 % BSA, 0.1 % gelatin, and 0.1 % Tween-20. Sections
were incubated (48 h at 4 °C) with the rabbit anti-D3R
antibody (1:2,000) in combination with the guinea pig anti-
body to the vesicular glutamate transporter 1 (VGluT1,
1:5,000; Chemicon, Temecula, CA, USA) or the antibody
to vesicular glutamate transporter 2 (VGluT2, 1:2500;
Chemicon, Temecula, CA), in TBS containing 5 % normal
donkey serum and 0.05 % Tween-20. After four washes in
TBS, 0.05 % Tween-20, sections were incubated for 1 h at
room temperature with the antibodies donkey anti-rabbit-
CY3 (1:200) and the donkey anti-guinea pig-Alexa-488
(1:200) (Molecular Probes, Corisbad, CA, USA) in TBS
0.05 %, Tween-20. Sections were washed, mounted on
Super Frost Plus slides, and then coverslipped using
Mowiol. Control experiments were performed to ensure that
each primary antibody did not react with the non-corresponding
secondary antibody conjugate. Immunostained sections
were analyzed and photographed on a Zeiss Axiophot
microscope.
Immunoelectron microscopy
Nucleus accumbens sections of three rats were blocked for
1 h (as for immunohistochemistry) and then incubated 72 h
at 4 °C with the rabbit anti-D3R antibody (1:2,000) in
0.05 M TBS, pH 7.4, containing 10 % normal donkey
serum. Some sections were incubated without the antibody
and used as control of specific immunostaining. After four
washes in 0.05 M TBS, pH 7.4, containing 0.1 % gelatin,
sections were incubated for 1 h at room temperature with
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biotinylated donkey anti-rabbit IgG (1:200; Amersham) in
0.05 M TBS, pH 7.4. Following rinsing (three times for
10 min) in 0.05 M TBS, pH 7.4, 0.1 % gelatin, sections were
incubated for 1 h at room temperature in avidin–biotin–HRP
complex (ABC reagent, Vectastain Elite; Vector Laboratories,
Burlingame, CA, USA). After peroxidase immunostaining,
sections were rinsed in 0.05 M PBS, pH 7.4; fixed for
10 min in 1 % glutaraldehyde, 0.05 M PBS, pH 7.4; and
then post-fixed for 20 min in 1 % osmium tetroxide. Brain
sections were dehydrated in a graded series of ethanol
solutions, impregnated with 1 % uranyl acetate in 100 %
alcohol, and infiltrated and flat-embedded in polymerized
epoxy resin. Pieces of epone-embedded sections were then
cut from the accumbens and glued to carrier blocks, and
ultrathin sections were cut from these specimens with a
Reichert ultramicrotome. Ultrathin sections were mounted
on mesh grids, stained with 0.4 % lead citrate and 4.0 %
uranyl acetate, and finally analyzed and photographed on a
JEOL 100 electron microscope.
Treatments for chronic NMDA receptor blockade
For chronic NMDA receptor blockade, dizocilpine was con-
tinuously infused for 7 days via osmotic minipumps (Model
1007D, Alzet Corp.) from day 0 to day 7. Minipumps were
filled 6 h prior to implantation and placed in a sterile saline
water bath at 37 °C. Taking into account the average mouse
weight at the time of testing and the delivery rate of mini-
pumps (specified by the manufacturer), we adjusted the
MK-801 concentration for a delivery of 0.02 mgkg-1h-1.
Mice were anesthetized with chloral hydrate (400 mgkg-1
i.p., Centravet, France) or isoflurane (O2 flow rate 2–3 lmin
-
1, induction 3.5 %, and maintenance 1.5–2.5 % isoflurane).
Mice were placed on a thermostatically controlled heating
pad connected to a rectal probe to maintain the animals in
homeothermic condition (37 °C) during surgery. An area on
the back of the mice was shaved and disinfected thoroughly
using Vétédine® (Centravet, France). A 1-cm incision was
made in the skin between the scapulae. Using a hemostat,
a small pocket was formed by spreading apart the sub-
cutaneous connective tissues. The pump was inserted into
the pocket, and the skin incision was closed with metallic
wound clips. The skin was again disinfected with
Vétédine®, and Négérol® spray (Centravet, France) was
sprayed on the wound. Mice were returned in their home
cage, and in about 2 h (chloral hydrate anesthesia) or
10 min (isoflurane anesthesia), they had fully recovered
and were active.
c-fos in situ hybridization
Saline or BP 897 (1 mgkg-1i.p.) was given twice daily for
4 days beginning 5.5 days after minipump implantation
(from day 5.5 to end of day 9), and animals were then
sacrificed on day 10 at least 14 h after the last injection,
when no more acute effect of drugs where observed. Their
brains were frozen in isopentane (−30 °C) and stored at
−80 °C until used. Slices (10 μm) were hybridized with a
33P-labeled antisense cRNA probe for c-fos mRNA. For c-
fos mRNA quantification, autoradiographic signals were
quantified on three to six slices per animal using an image
analyzer (IMSTAR, France). Gray values were converted to
microcurie per milligram dry weight using C14 standard
stripes (Amersham). For c-fos mRNA imaging, slices were
hybridized with a [33P]-labeled c-fos cRNA probe and a
digoxigenin-labeled VGluT1 cRNA probe (the plasmid con-
taining cDNA encoding VGluT1 was generously donated
by S. El Mestikawy). The hybridized slices were dipped into
the photographic emulsion, and silver grain density was
assessed in discrete neuronal populations using “Grain®”
imaging software (IMSTAR, France). Briefly, silver grains
were counted over randomly selected VGluT1-labeled neu-
rons from the prefrontal cortex for each animal (60–80 cells)
in three separate sections.
Electrophysiological recordings
Saline or BP 897 (1 mgkg-1i.p.) was given twice daily for
4 days beginning 5.5 days after minipump implantation
(from day 5.5 to end of day 9), and animals were then
sacrificed on day 10 at least 14 h after the last injection,
when no more acute effects of drugs were observed. At day
10, mice were sacrificed, and their brains were rapidly
removed and transferred to a chilled (4 °C) slicing solution
equilibrated with a 95:5 % mixture of O2 and CO2. Coronal
slices (300 μm thick) were prepared on a vibratome (blade
angle, 18°) and transferred to a humidified interface cham-
ber at 33 °C. The slices were superfused with oxygenated
artificial cerebrospinal fluid (ACSF: 126 mM NaCl, 26 mM
NaHCO3, 3 mM KCl, 1.25 mM NaH2PO4, 2 mM MgCl2,
2 mM CaCl2, and 10 mM glucose; pH 7.4) at a rate of
2.5 mlmin-1 for 90 min before recordings began. There
was usually one slice in each hemisphere with the cortex
of interest. Extracellular field potentials were recorded using
borosilicate glass microelectrodes filled with ACSF (1–2
MΩ). A microelectrode was placed in the middle layers of
the prelimbic cortex, and a bipolar stainless steel stimulating
electrode was placed in the underlying white matter.
Electrodes were positioned to provide the lowest stimulation
threshold to evoke a response and the smallest possible
stimulation artifact. For a given configuration, the threshold
for triggering a response was determined using single
shocks (80-μs square direct current (DC) pulses), and the
stimulus intensity was then set at three times this threshold
for the rest of the experiment. A common stimulation se-
quence was programmed using the Spike2® programming
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language. The stimulation sequence began with and ended
with a series of 12 single shocks delivered every 5 s; the
initial single-shock series was followed, after a 30-s silent
period, by a series of paired stimuli delivered every 10 s.
Each pair of stimuli had an interpulse interval that was
shortened by half that of the preceding one starting from
1,000 ms down to 7.8 ms. The sequence with varying
interpulse intervals was repeated eight times.
The signal was amplified (×1,000) and filtered (DC
3 kHz, analog filter) before being digitized (10 kHz) using
a CED 1401 interface and the Spike2® software (Cambridge
Electronic Design, UK). In an off-line analysis, the 12
single-shock responses and the eight pairs of responses to
paired shocks with the same interpulse interval were aver-
aged for visual inspection and comparison. For each re-
sponse, the amplitude was computed by a homemade
program as the difference between the maximum potential
value and the minimum potential value in a time range that
was predetermined by visual inspection. For each pair of
stimuli, the ratio of the second response amplitude to the
first one was computed to normalize the measurements.
Again, the resulting ratio for the eight pairs of responses to
paired shocks with the same interpulse interval was then
averaged.
Locomotor activity after acute NMDA receptor blockade
The procedure has been described previously (Leriche et al.
2003) with small adaptations. Briefly, mice were injected
with either saline or F17141 at doses of 0.16, 0.63, 2.5, or
10 mgkg-1i.p., and their horizontal locomotor activity was
measured for 30 min (spontaneous locomotor activity).
They were subsequently treated with 0.9 % NaCl (saline)
in a volume of 10 mlkg-1 or dizocilpine (0.14 mgkg-1i.p.),
and the activity was measured for 1 h (MK-801-induced
locomotor activity). The locomotor activity was measured in
an actimeter that was composed of eight individual activity
cages (30×15×18 cm, with sawdust on the floor) transected
by infrared beams (Imetronic, Pessac, France). Counts for
forward horizontal activity were incremented each time the
animal moved from one-half part of the cage to the other,
corresponding to disruption of two crossed parallel beams
distant of 14 cm.
Resident–intruder assay after chronic NMDA receptor
blockade
Male mice were housed individually (residents) or in groups
of five (intruders) for 1 week prior to minipump implanta-
tion (see above), delivering MK-801 (0.02 mgkg-1h-1s.c.) or
saline (Sham) as described above. Following recovery, they
were housed again in the same condition for 7 days and then
tested in a “resident–intruder” paradigm adapted from
(Dixon et al. 1994; Mohn et al. 1999) with some modifications.
In the original test, a resident mouse is housed alone for
2 weeks, and then, a group-housed intruder is introduced to
the resident cage. In our experiments, for convenience of
observation, group-housed intruder and isolated resident
were not confronted in the resident cage but in a test arena
(34 cm×34 cm×30 cm, l×L×h) with sawdust on the floor.
Sawdust will be replaced between each habituation or test
session. At the end of a day of experiments, the arena will
be cleaned using 70 % EtOH. Even with these modifica-
tions, the behaviors displayed by both group of mice were
almost the same as those observed in the original con-
ditions cited above (Leriche, personal observations; see
“Results and discussion”). To minimize the incidence of
stress on social behavior, mice were habituated the day
before the test day 6 min to the test arena. In these
conditions, placing the animals in test arena was as less
aversive as possible.
The day before the resident–intruder social interaction
test, all the mice from the intruder groups were labeled with
a different color code with a permanent marker to differen-
tiate them during the test session. Thirty minutes prior to
testing, saline, F17141 (0.16, 0.63, 2.5, or 10 mgkg-1), or
clozapine (1 mgkg-1) were administered to the resident and
intruder mice. As described previously, a group-housed
male (intruder) and an individually housed male (resident)
from the same treatment group (i.e., saline-resident and
saline-intruder, etc.) were introduced in the test arena, and
their behaviors were video-recorded for 6 min. The video-
taped behaviors of the resident and intruder mice were
individually scored for time spent in social investigation
(approaching, sniffing, grooming other mouse, and sexual
behavior), in escape behavior (actively avoiding the unfamil-
iar congener), and fighting. Typically, the resident actively
initiates social investigations of the intruder, sometimes initi-
ating fights, and rarely avoids social interaction by escape
(Dixon et al. 1994; Mohn et al. 1999).
Statistical analysis
Between-groups differences were analyzed with the
StatisticaTM software using two-way analysis of variance
(ANOVA) and the least significant difference (LSD) post
hoc test. For analysis of data obtained with the same animals
evaluated on several occasions (e.g., time-course experi-
ments), between–within univariate or multivariate ANOVA
for repeated measures was used (with time being the repeated
measure). Data from paired-pulse electrophysiology
experiments and c-fos mRNA distribution histogram were
analyzed by between–within univariate or multivariate
ANOVA for repeated measures (with interpulse interval
and number of grain/cell being the repeated measures,
respectively).
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Results and discussion
Direct interactions of the D3 receptor with glutamate
In rat brain, the largest receptor densities occur in granule
cells of the islands of Calleja and in medium-sized spiny
neurons of the rostral and ventromedial shells of nucleus
accumbens, which coexpress the D1 receptor, substance P,
dynorphin, and/or neurotensin (Diaz et al. 1995; Le Moine
and Bloch 1996). These output neurons from the nucleus
accumbens receive their dopaminergic innervations from the
ventral tegmental area and reach the entorhinal and prefron-
tal cortex after relays in the ventral pallidum and mediodor-
sal thalamus. In turn, the shell of nucleus accumbens
receives projections from the cerebral cortex (infralimbic,
ventral, agranular, insular, and piriform areas), hippocam-
pus, and amygdala and also projects to the ventral tegmental
area from which dopaminergic afferents originate (Zahm
and Brog 1992; Pennartz et al. 1994). These various specific
connections of the shell of nucleus accumbens, a part of the
“extended amygdala” (Heimer 2000), suggest that this area
is involved in a series of feedback or feed-forward loops,
involving notably the prefrontal cortex and ventral tegmen-
tal area and subserving control of emotions, motivation, and
reward. In the human and non-human primate brains, the
phenotype of neurons expressing the D3 receptor is not yet
identified, but several studies show their distribution to be
rather similar to that in the rat, with, however, higher densities
and larger distribution in the ventral part of the caudate
putamen and the cerebral cortex (Landwehrmeyer et al.
1993; Hall et al. 1996; Girgis et al. 2011; Gallezot et al. 2012).
We carried out ultrastructural analysis to determine the
subcellular distribution of the D3 receptor in the nucleus
accumbens of rats. We have used electron transmission
microscopy and immunostaining with a specific anti-D3
receptor antibody, which was thoroughly validated by im-
munoprecipitation of solubilized D3 receptor binding, over-
lapping of immunolabeling with D3 receptor binding, and
suppression of immunolabeling in D3 receptor-deficient
mice (Diaz et al. 2000). The peroxidase immunoreactivity
was often detected at the level of dendritic spines in
medium-sized spiny neurons. Figure 1a–d shows four exam-
ples of electron-dense peroxidase reaction product concen-
trated at the level of asymmetric synapses at the head of
dendritic spines. We estimated that 64 % of immunolabeling
was associated with asymmetric synapses (30 positive over
47). The synaptic localization of the D3 receptor is in
marked contrast with those of D1 and D2 receptors, which
are either perisynaptic or spread all over dendrites and
dendritic spines in medium-sized spiny neurons of striatum
(Hersch et al. 1995; Delle Donne et al. 1997) and nucleus
accumbens (Hara and Pickel 2005; 2007; Pickel et al. 2006).
Very surprisingly, most of the D3 receptor-positive synapses
are of asymmetric type, which is a typical feature of gluta-
matergic synapses (Uchizono 1965; Kemp and Powell
1971), whereas the majority of presumed dopamine termi-
nals form symmetric synapses (Bolam et al. 2000; Arluison
et al. 1984). Immunoreactivity associated to symmetric
synapses (Fig. 1) was rarely observed in this study.
Interestingly, in the examples shown, labeled synapses are
all contained in the head of spines, particularly identifiable
in the sagittal section of a spine depicted in Fig. 1d. Cortical
glutamatergic terminals form asymmetric synapse at the
head of dendritic spines on medium-sized spiny neurons of
striatum, whereas other afferences mainly contact dendritic
necks or shafts (Bolam et al. 2000). The localization of D3
receptor labeling at the vicinity of glutamatergic terminals
was confirmed by double fluorescence labeling experiments
(Fig. 2) with an antibody directed against the vesicular
transporter 1 (VGluT1), a marker of glutamatergic terminals
of neurons originating from the cerebral cortex, amygdala,
or hippocampus, but not thalamus, which express VGluT2
(Hartig et al. 2003). Figure 2 shows that VGluT1 and D3
receptor immunofluorescences are detected as tiny puncta
occupying the neuropil and displaying a clear association.
Of course, the resolution of the technique does not permit us
to go deep into the physical association between the two
immunomarkers. Nevertheless, there seems to be no strict
colocalization of D3 receptor and VGluT1; rather, they
appear apposed each other, particularly in the left bottom
part of Fig. 2 (arrows), possibly reflecting the glutamatergic
terminal/dendritic spine apposition. Thus, both ultrastructural
study and double immunofluorescence experiments suggest
the presence of the D3 receptor at glutamatergic synapses in
medium-sized spiny neurons of nucleus accumbens.
There are two implications to the peculiar localization of
the D3 receptor at glutamatergic synapses. The first one
deals with a fundamental issue of neurotransmission that is
volume transmission. Classical fast neurotransmission by
excitatory (glutamate, aspartate) or inhibitory (γ-amino-
butyric-acid (GABA), glycine) amino acids operates
through voltage- and calcium-dependent release of the neu-
rotransmitter into the synaptic cleft, stimulation of neuro-
transmitter receptors located at the other edge of the
synaptic cleft in specialized post-synaptic domains, and
termination of the signal by receptor desensitization and
neurotransmitter reuptake. Other neurotransmitters, such as
monoamines or neuropeptides, can exert their action
through a second, much slower, non-synaptic diffuse mode
of neurotransmission called volume transmission (Zoli et al.
1999). Considering that asymmetric synapses bearing the D3
receptor are formed with edges of glutamatergic terminals
located at some distance of dopamine terminals, the D3
receptor transmission uses a peculiar and unprecedented
variety of volume transmission, in which released dopamine
diffuses and dilutes over some distance in the interstitial
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space, to stimulate post-synaptic receptors of distal non-
dopaminergic synapses. This mode of transmission also
differs from “spillover” transmission of glutamate or
GABA, in which the released neurotransmitter diffuses before
targeting a distal homologous synapse (Kullmann 2000).
Volume transmission through the D3 receptor is possible
owing to its higher affinity for dopamine, as compared to
other dopamine receptor subtypes (Sokoloff et al. 1990).
The second issue is the functional role of D3 receptor at
glutamatergic synapses, which bear α-amino-3-hydroxy-5-
methyl-4-isoxazole-propionic acid (AMPA) and N-methyl-D-
aspartate (NMDA) receptors (Bernard et al. 1997; Bernard
and Bolam 1998) at the post-synaptic site. Liu and col-
leagues elegantly addressed this question (Liu et al. 2009).
They showed that the D3 receptor binds to Ca
2+/calmodulin-
dependent protein kinase II (CaMKII) in a Ca2+-dependent
Fig. 1 Immunoperoxidase labeling for the D3 receptor in the nucleus
accumbens of rat brain. Electron micrographs of the nucleus accum-
bens shell immunostained by the avidin–biotin–peroxidase complex
(ABC) method to reveal immunoreactivity for the D3 receptor (anti-D3
receptor antibody, 1: 2,000; see Diaz 2000). Images (a–d) showing that
immunoreactivity for D3R, is localized at asymmetric synapses in
dendritic spines (ed) in medium-sized spiny neurons of the nucleus
accumbens. Note the high density of labeling in, or near, the region of
the post-synaptic density at the head of dendritic spines (particularly
visible in a sagittal section of a dendritic spine in d), which is juxta-
posed to presynaptic terminal profiles (t), containing clear vesicles and
forming asymmetric synapses. Image (e) shows immunoreactivity for
D3R in a dendrite profile (d) apposed to an unlabeled axon terminal (t)
that forms a symmetric synapse. Scale bar 0.25 μm
Fig. 2 Colocalization of D3 receptor (a) and VGluT1 (b) immunore-
activity in the nucleus accumbens. Representative distribution of
fluorescent signals generated in double immunostained rat brain
sections using a rabbit polyclonal antibody directed against the D3
receptor (D3R) and guinea pig polyclonal antibodies directed against
the vesicular glutamate transporter 1 (VGluT1) to reveal association of
post-synaptic D3R with presynaptic glutamatergic inputs. a Dot-like
red-fluorescent immunoreactivity displayed for the D3R. b Dense
immunofluorescent staining for the VGluT1. c Close association of a
large-proportion D3R immunostaining with presynaptic glutamatergic
terminals immunolabeled with the anti-VGluT1 antibody
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manner. This interaction involves the third intracellular loop
of the receptor and occurs in the post-synaptic densities
(PSD)-enriched fraction of accumbal neurons, but not in
other D3-expressing neurons in the substantia nigra or ventral
tegmental area. PSD are associated with glutamatergic synap-
ses, which confirms the site of interactions. NMDA receptor
activation that increases intracellular Ca2+ stimulates D3 re-
ceptor–CaMKII interactions. D3 receptor–CaMKII interac-
tions further impact downstream effectors of cyclic AMP/
protein kinase A, such as other constituents of the glutamater-
gic synapses, such as AMPA receptor GluR1 subunit. In turn,
D3 receptor–CaMKII interactions downregulate D3 receptor
functions. A reciprocal regulation of glutamate and dopamine
at synaptic glutamatergic synapses is a result from this pro-
cess, by which D3 receptor function is exacerbated in con-
ditions of NMDA receptor blockade, a situation that mimic
psychotic symptoms. Indeed, phencyclidine (PCP), a non-
competitive antagonist at the NMDA receptor, is an anesthetic
agent that has dissociative and psychotomimetic properties in
man (Javitt and Zukin 1991). PCP produces a state of sensory
isolation, seeming “drunkenness” and hallucinations, often
followed by a feeling of depersonalization in abusers
(Snyder et al. 1981), and schizophrenic-like symptoms in
healthy volunteers (Jentsch and Roth 1999; Luby et al.
1959). Psychotic symptoms induced by PCP, or the pharma-
cologically related compound ketamine, include both positive
(hallucinations, delusions) and negative (formal thought
disorder, social withdrawal) symptoms, as well as cognitive
dysfunction (Cosgrove and Newell 1991). Therefore, the
considerations above support the view that blockade of D3
receptor could reverse the effects of NMDA receptor blockade
and elicit antipsychotic-like actions.
Indirect interactions of the D3 receptor with glutamate
The glutamate theory owned its birth from the fortuitous
observation that PCP and ketamine, originally developed as
anesthetics, possessed psychotomimetic potential. Eventually,
they were discovered to be non-competitive NMDA recep-
tor blockers (Javitt and Zukin 1991). Subsequently, a theory
was developed postulating a reduced NMDA function in
schizophrenia (Goff and Coyle 2001). However, the concept
has progressively emerged that the dysfunction of glutamate
was rather hyperfunction, through exacerbated glutamate
release from hyperexcitable cortical pyramidal cells and
activation of AMPA receptors. The most conceptualized
version of the glutamate theory (Moghaddam and Javitt
2012) now indicates that hyperexcitability of pyramidal
cells results from a loss of inhibition of GABAergic inter-
neurons, which can be mimicked by blocking NMDA recep-
tors expressed by these neurons. This results in enhanced
electrical spike activity and disorganization of the firing of
cortical neurons, adding “noise” and interrupting the ability
of these neurons to process information. This also results in
enhanced glutamate by pyramidal cells that project to
various subcortical areas, including striatum and nucleus
accumbens.
Anatomically, dopamine-immunoreactive terminals of
the mesocortical pathway converge on pyramidal cells and
parvalbumin-positive fast-spiking interneurons (Gaspar et
al. 1995; Verney et al. 1990; Sesack et al. 1995; 1998;
Gorelova et al. 2002; Sesack et al. 1995; 1998). The activity
of cortical cells is controlled by dopamine in a rather
complex manner because D1 and D2 receptors can exert
both facilitation or inhibition of cell firing on excitatory
pyramidal cells and the inhibitory interneurons (Seamans
and Yang 2004). Schematically, D1 receptor-mediated
effects include an increase in NMDA currents, a decrease
in glutamate release, and an increase in interneuron excit-
ability and inhibitory post-synaptic current amplitude in
pyramidal cells, whereas D2 receptor-mediated effects in-
clude a reduction of inhibitory post-synaptic currents onto
pyramidal cells and reduction of NMDA currents and spik-
ing. This complex modulation by dopamine of the prefrontal
cortex maintains coherent activity that is crucial for task-
dependent neuronal activity, decision-making assessed with
delay discounting and effort-based procedures (Goldman-
Rakic et al. 2004; Seamans and Yang 2004; Floresco and
Magyar 2006).
D3 receptors are virtually absent from the prefrontal
cortex (Bouthenet et al. 1991; Diaz et al. 1995), but local
injections of selective D3 antagonists in the prefrontal cortex
induced cognitive improvement (Loiseau and Millan 2009),
suggesting that, despite their low expression in this brain
area, the functional role of D3 may not be negligible. In
medium-sized GABAergic neurons of the nucleus accum-
bens, the D3 receptor is not only expressed on the dendritic
spines, but also on terminals of these neurons projecting to
the lateral part of the ventral tegmental area and medial part
of substantia nigra of the mesencephalon. This was demon-
strated by lesions with kainate of the accumbal neurons,
which produced a similar decrease in D3 receptor binding
at the site of the lesion and in the mesencephalon (Diaz et al.
2000). The expression of the D3 receptor at the terminals of
descending accumbal GABAergic neurons makes the major
part of the D3 receptor binding in the ventral tegmental area/
substantia nigra, which can be labeled as the selective D3
receptor ligands [3H]-7-OH-DPAT (Levesque et al. 1992) or
[125I]-7-OH-PIPAT (Stanwood et al. 2000) in receptor
autoradiography experiments on brain slices, as well as in
PET studies with [11C]-(+) PHNO (Narendran et al. 2006;
Graff-Guerrero et al. 2009b; Rabiner et al. 2009; Gallezot et
al. 2012). In addition, D3 receptors are also expressed by
dopamine neurons in the ventral tegmental area and sub-
stantia nigra: D3 receptor mRNA is expressed in dopamine
neurons (Diaz et al. 1995), and its expression decreases after
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lesion of these neurons by 6-hydroxydopamine (Lévesque et
al. 1995); all dopamine neurons identified by positive
immunoreactivity to tyrosine hydroxylase also express the
D3 receptor protein detected by immunoreactivity (Diaz et
al. 2000).
It can be hypothesized that the D3 receptor exerts a tonic
inhibition on dopamine neurons in the ventral tegmental
area projecting to the nucleus accumbens, either by stimu-
lating GABA release at accumbal neuron terminals or by an
autoreceptor control. Several lines of evidence support this
conclusion. First, dopamine release (Tang et al. 1994) and
synthesis (O'Hara et al. 1996) are inhibited by stimulation of
the D3 receptor expressed in a transfected mesencephalic
cell line and various agonists, with limited preference for the
D3 receptor (Sautel et al. 1995), and inhibit dopamine re-
lease and synthesis and neuron electrical activity (Levant
1997), giving support to the existence of D3 autoreceptors.
However, the selectivity of these agonists toward the D3
receptor in vivo has been strongly questioned because they
elicit similar inhibition of dopamine neuron activities in
wild-type and D3 receptor-deficient mice (Koeltzow et al.
1998). In addition, dopamine autoreceptor functions are
suppressed in D2 receptor-deficient mice (Mercuri et al.
1997; L'hirondel et al. 1998). Nevertheless, dopamine ex-
tracellular levels in the nucleus accumbens (Koeltzow et al.
1998) and striatum (Joseph et al. 2002) are twice as high in
D3 receptor-deficient as in wild-type mice, suggesting a
control of dopamine neurons activity by the D3 receptor.
The hypothesis of a control exerted by D3 autoreceptors is
also supported by the observations that D3 receptor-deficient
mice display signs reminiscent of hyperdopaminergia, pre-
sumably resulting from the lack of autoreceptors controlling
dopamine neuron activity (Accili et al. 1996). Furthermore,
blocking the D3 receptor by selective antagonists increases
extracellular levels of dopamine in the prefrontal cortex
(Lacroix et al. 2003), a projecting area of mesencephalic
dopamine neurons.
Hence, the negative control that the D3 receptor may
exert on dopamine neurons, directly by its autoreceptor
function or indirectly through the control of GABA release,
results in a downregulation of dopamine release in the
prefrontal cortex and, consequently, an excitation of glutamate
pyramidal cells. This control is relevant to schizophrenia
because it is now well accepted that dopamine deficiency
in the prefrontal cortex is a hallmark of the disease (Davis et
al. 1991; Abi-Dargham 2004; Carlsson and Carlsson 2006).
This feature has recently received a strong support from a
PET studies, showing that amphetamine-induced dopamine
was reduced in the prefrontal cortex of schizophrenic
patients (Abi-Dargham 2011), although it has been repeat-
edly shown to be increased in subcortical areas such as the
striatum (Laruelle et al. 1996; Abi-Dargham et al. 1998).
Furthermore, D3 receptor expression may be upregulated in
the post-mortem brain of schizophrenic patients (Gurevich
et al. 1997), which may contribute to accentuating dopamine
deficiency in the prefrontal cortex; however, upregulation
of D3 receptors in schizophrenia has not been confirmed
in one PET study (Graff-Guerrero et al. 2009b). It is
therefore conceivable that D3 receptor antagonists, by
relieving the break exerted by D3 receptors onto dopamine
mesocortical neurons, may correct dopamine deficiency in
the prefrontal cortex and normalize glutamate pyramidal
cell activity.
The normalization of glutamate activity by D3 receptor
blockade was studied using functional neuroimaging based
on quantification of c-fos mRNA expression, a non-specific
marker of neuronal activity, in a mouse model of chronic
NMDA receptor blockade. Indeed, chronic exposure of
humans to NMDA antagonists seems to mimic schizophre-
nia better than acute exposure: Hallucinations are mainly
auditory and are accompanied by negative symptoms and
cognitive deficits (Jentsch and Roth 1999). Chronic NMDA
receptor blockade was obtained by a 7-day continuous in-
fusion of the highly potent and selective non-competitive
NMDA antagonist dizocilpine (MK-801). MK-801 was in-
fused (0.02 mgkg-1h-1) via subcutaneously implanted os-
motic minipumps from day 1 to 7. To specifically block the
D3 receptor, we used BP 897, a D3 receptor-selective partial
agonist with an intrinsic activity of ~0.5 in a heterologous
expression system (Pilla et al. 1999), which also has antag-
onist properties in vivo (Preti 2000). BP 897 was subchroni-
cally administered for 4.5 days at a dose of 1 mgkg-1i.p.
twice a day, starting 4.5 days after minipump implantation
(day 5 to 9). The animals were sacrificed at day 10, when
MK-801 and BP 897 no longer have acute effect but when
some behavioral abnormalities were still present in MK-
801-treated mice and normalized by BP 897 subchronic
treatment (unpublished results). When observed and quan-
tified on film autoradiographs, c-fos mRNA levels were
significantly reduced in the medial prefrontal cortex
(mPFC) after treatment with MK-801, and this effect was
at least reduced after BP 897 administration (Fig. 3a, b). No
trend toward changes in c-fos expression was observed in
other brain regions (not shown). The effects of BP 897 alone
were not quantified in these experiments, but a pharmaco-
logical analog of BP 897 did not increase c-fos expression in
the prefrontal cortex (Southam et al. 2007). We performed a
more precise analysis and grain counting at the microscopic
level after double hybridization with a cRNA probe that
labels transcripts of VGluT1. At the level of mPFC in
control animals, 54±2 % (n06, 630–828 neurons counted
per animal) of VGluT1-positive neurons expressed c-fos
(Fig. 3c), and this percentage did not change after treatment
(56±3 %, n06, and 54±3 %, n06, in animals receiving
MK-801 and MK-801+BP 897, respectively). The number
of c-fos-positive neurons exceeded by 25–40 % the number
Naunyn-Schmiedeberg's Arch Pharmacol (2013) 386:107–124 115
of double-positive neurons, indicating that c-fos is mainly,
but not exclusively, an index of glutamatergic neuron
activity in the mPFC. Analysis of the distribution of c-fos-
positive neurons revealed that c-fos mRNA levels globally
decreased following treatment with MK-801 in a large
fraction of the neuronal population, expressing moderate to
low levels of c-fos mRNA (number of grains lower than 20
or comprised between 40 and 60), which is shown by the
leftward shift of the distribution curve (Fig. 3d). The
distribution curve after MK-801+BP 897 was more similar
to that obtained in control animals. In animals receiving
MK-801, we also observed the appearance of heavily c-
fos-labeled neurons (>200 grains/cell, arrows in Fig. 3c),
which were all VGluT1 positive and rarely encountered in
the other experimental conditions. The results indicate that
NMDA receptor blockade induced changes in mPFC func-
tion, including both neuronal hypofunction and heteroge-
neous hyperactivity.
Fig. 3 Functional imaging measured by c-fos expression in mPFC
after chronic NMDA-R blockade by MK-801, showing mPFC
dysfunction reversed by BP 897. Animals received a 7-day continuous
infusion of saline and a saline subchronic treatment (Sham+Sal) or a
continuous infusion of MK-801 and a subchronic 4.5-day treatment
with either saline (MK-801+Sal) or BP 897 (1 mgkg-1, MK-801+BP
897), as described in “Methods.” Then, at day 10, they were sacrificed,
and the brain was processed for double in situ hybridization with a
[33P]-labeled c-fos cRNA probe and a digoxigenin-labeled cRNA
probe that corresponds to the sequence encoding the vesicular gluta-
mate transporter type I (VGluT1), a marker of glutamatergic neurons. a
Film autoradiography of c-fos mRNA signals. Coordinate from bregma
1.94 mm. b Quantitative analysis of autoradiographic pictures of c-fos
mRNA signals in the mPFC. Results are mean±SEM. (n05–6).
Significant effect of treatment (F2,1404.24, P00.036), *P<0.02 vs.
Sham+Sal or MK-801+BP 897. c Microphotographs showing c-fos
(dark dots) and VGluT1 (pink color) signals. Treatment with MK-801
induced the appearance of heavily labeled neurons (arrows). Bar:
50 μm. d Distribution of c-fos-labeled neurons according to c-fos
mRNA level (measured as number of grain per cell) in the prelimbic
cortex subregion of the mPFC. On each animal, 60 to 80 neurons
were analyzed, and there were five to six animals per treatment
group. Significant treatment×distribution interaction (F20,15003.38,
P<0.0001). *P<0.05; **P<0.01 vs. Sham+Sal; ***P<0.001; #P<0.05;
##P<0.01 vs. MK-801+Sal
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In the same animal model, i.e., continuous 7-day MK-
801 treatment and 4-day subchronic BP 897 treatment, the
changes in the electrical activity of mPFC efferent glutama-
tergic neurons were assessed by measuring paired-pulse
facilitation of field potentials after orthodromic stimulation
in slices. For this, a recording electrode was placed in the
middle layer of the prelimbic cortex (PrL), a part of mPFC
containing glutamatergic neurons that provide direct excit-
atory inputs to the shell part of nucleus accumbens, where
the D3 receptor is expressed (Fig. 4a). Trains of double
pulses, with varying interpulse intervals, were applied on
afferent excitatory fibers to the mPFC with a bipolar elec-
trode placed on the underlying white matter (Fig. 4a). At a
short interpulse interval (7.8 ms) in control animals, paired-
pulse depression was observed, i.e., the amplitude of the
response to the second pulse was lower than that to the first
(Fig. 4c). At an interpulse interval of 31.2 ms, paired-pulse
facilitation (~ +20 %) was observed and disappeared at
longer intervals (>62.5 ms). In animals receiving MK-801,
paired-pulse facilitation was largely and significantly in-
creased (>+40 % at an interval of 62.5 ms; see Fig. 4b) and
was maintained elevated at long intervals (up to 1,000 ms; see
Fig. 4c). In animals receiving MK-801+BP 897, paired-pulse
depression was significantly increased for short interpulse
intervals (<31.2 ms) as compared to control animals, and
paired-pulse facilitation returned to control at longer intervals
(Fig. 4b, c). These results demonstrate long-lasting hyperres-
ponsiveness of mPFC efferent glutamatergic neurons after
NMDA hypofunction and normalization by D3 receptor
blockade. This effect is supposed to be exerted indirectly, but
further studies will be necessary to address whether it involves
modulation of dopamine release in the prefrontal cortex.
Fig. 4 Neuronal hyperresponsiveness in prefrontal cortex after chronic
NMDA-R blockade by MK-801, assessed by paired-pulse facilitation,
and normalization by BP 897. Slices were prepared from animals
receiving continuous infusion of saline and a saline subchronic treat-
ment (Sham+Sal) or a continuous infusion of MK-801 and a sub-
chronic treatment with either saline (MK-801+Sal) or BP 897 (1 mg
kg-1, MK-801+BP 897) sacrificed 3 days after continuous MK-801
cessation and at least 16 h after the last injection. a Field potentials
were recorded with an electrode placed in the middle layers of the
prelimbic cortex (PrL) after stimulation in the adjacent region. Ac
nucleus accumbens core, As nucleus accumbens shell, cc corpus cal-
losum, Cg cingulate cortex, Cpu caudate-putamen, IL infralimbic
cortex, M1 primary motor cortex, M2 secondary motor cortex, Sm
primary sensorimotor cortex. b Field potentials after paired-pulse
stimulation with an interpulse interval of 62.5 ms. Traces are means of
eight successive recordings performed on a representative animal of
each group treatment. Artifacts immediately following stimulation
were removed for clarity. Color codes as in c. c Paired-pulse facilita-
tion, measured as the ratio of amplitudes of responses to the second
and first stimulations, as a function of the interpulse interval.
Results are mean±SEM. of averaged ratios recorded in five to
six animals. There were significant effects of interpulse interval
(F7,98016.55, P<0.00001). *P<0.05; ** P<0.01
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D3 receptor antagonists in preclinical models
of schizophrenia based on N-methyl-D-aspartate receptor
blockade
The psychotic effects of dissociative anesthetics acting by
blocking the NMDA receptor in humans (see above) repre-
sent not only a conceptual framework for understanding
schizophrenia, but also an impressive pharmacological mod-
el of the disease. Indeed, behavioral abnormalities elicited
by PCP, ketamine, or MK-801, a more selective NMDA
receptor blocker, have been used to model symptoms of
schizophrenia in animals and to detect antipsychotic-like
properties of drugs (Corbett et al. 1995; Jentsch and Roth
1999; Bradford et al. 2010; Adell et al. 2012). In rodent,
these drugs elicit hyperactivity and stereotypies that can be
reversed by treatment with antipsychotic drugs. We have
shown that hyperactivity induced by MK-801 was largely
reduced in D3 receptor-deficient mice and readily antago-
nized by the D3 receptor-selective partial agonist BP 897
(Leriche et al. 2003). We have now extended this observa-
tion to several D3 receptor-selective antagonists (Table 1). In
the test, we are measuring the effects of tested agents on
both spontaneous locomotor activity and MK-801-induced
hyperactivity (Leriche et al. 2003). In general, D3 receptor-
selective antagonists or partial agonists reduced MK-801-
induced hyperactivity at lower doses than those that reduced
spontaneous activity. This was not the case of haloperidol
((Leriche et al. 2003) Table 1).
We also tested F17141, a novel D3 antagonist, which
exhibits a 355 time higher affinity at D3 receptors compared
to D2 receptors (Sokoloff et al. 2008). Interestingly, F17141
completely antagonized the MK-801 stimulant effect and
did so with little or no effect on spontaneous activity
(Fig. 5), suggesting an antipsychotic-like effect at doses
much lower than purely sedative ones. In this respect, the
profile of F17141 is more similar to that of clozapine and of
other D3 receptor antagonists than that of haloperidol
((Leriche et al. 2003) (Table 1).
Seven-day continuous infusion of MK-801 (0.02 mgkg-1h-1)
via subcutaneously implanted osmotic minipumps elicited
social interaction deficits in mice in a “resident–intruder”
paradigm adapted from (Dixon et al. 1994; Mohn et al.
1999) with some modifications. In the original test, a resi-
dent mouse is housed alone for 2 weeks, and then, a group-
housed intruder is introduced to the resident cage. In our
experiments, for convenience of observation, group-housed
intruder and isolated resident were not confronted in the
resident cage but in a test arena, to which both where
individually habituated before confrontation. Even with that
modification, the behaviors displayed by both groups of
mice were almost the same as those observed in the original
conditions cited above (Leriche, personal observations).
Typically, the resident actively initiates social investigations
of the intruder, sometimes initiating fights, and rarely avoids
social interaction by escape (Dixon et al. 1994; Mohn et al.
1999). Social interaction deficits in the resident–intruder test
consisted of both a reduction in social investigations and an
increase in escape behavior displayed by the resident mice.
Acute treatment with F17141 of the resident and intruder,
30 min before confrontation, dose dependently and com-
pletely inhibited the social investigation deficit and escape
behavior induced by MK-801, with ID50 values of 0.49 and
0.32 mgkg-1i.p., respectively (Fig. 6). Clozapine, at a dose
of 1 mgkg-1i.p., also completely inhibited the social inter-
action deficits and escape behavior in this same test (Fig. 6),
as well as did BP 897, at a dose of 1 mgkg-1i.p. (not shown).
However, haloperidol was inactive at 0.1 mgkg-1, a dose at
which it does not produce catalepsy (not shown).
Table 1 Effects of D3 receptor antagonists and partial agonists, compared to selected antipsychotics in the MK-801 test in the mouse
Compound D3/D2L selectivity








Aripiprazole 0.32 0.48 0.21 2.3
Haloperidol 0.41 0.21 0.08 2.6
Clozapine 0.52 6.3 0.49 13
Cariprazine 5.8 0.11 0.02 5.5
ABT-925 17.3 9.8 < 0.16 >61
BP 897 281 7.7 0.40 19
S33084 324 >10 1.5 6.6
SB-277011A 871 28 14 2
F17141 151 >10 0.28 >36
a Ratio of Ki values for inhibiting [
3 H]-spiperone binding at recombinant human D2L and D3 receptors (Newman-Tancredi et al. 2007)
b Spontaneous locomotor activity was recorded during the 30-min phase of habituation in the actimetry cage
c Hyperactivity was measured during 90 min following injection of MK-801 (0.14 mgkg-1 i.p.)
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Taken together, the results obtained with F17141 and
other D3 receptor antagonists indicate that blocking the D3
receptor produces antipsychotic-like effects in mouse
models mimicking both positive and negative symptoms.
These results are consistent with the observations that
disruption by NMDA receptor blockers of glutamate
homeostasis leads to hyperexcitation of pyramidal cells
and increased glutamate release in the prefrontal cortex
(Moghaddam and Javitt 2012) and presumably subcortical
areas including the nucleus accumbens and with the evi-
dence presented above that D3 receptor antagonists can
oppose the effects of NMDA blockade by acting directly
at post-synaptic levels and indirectly at presynaptic levels
on pyramidal cells. Moreover, D3 antagonists have con-
sistently showed ability to increase cognitive performance
or to reverse cognitive deficits in rodents and monkeys
(Sigala et al. 1997; Loiseau and Millan 2009; Laszy et al.
2005; Millan et al. 2010; Watson et al. 2012a; Watson et
al. 2012b). They also support the use of D3 receptor-
selective antagonists in the treatment of positive and
negative symptoms of schizophrenia, as well as cognitive
deficits associated with the disease.
Fig. 5 F17141 had no effect on spontaneous horizontal locomotor
until 10 mgkg-1i.p. (a) and dose dependently antagonized the stimulant
effects of acute NMDA-R blockade by MK-801 (b) in mice. F17141
(0.16–10 mgkg-1, i.p.) or saline (Sal) was injected, and spontaneous
behaviors were recorded during 30 min (a). MK-801 (0.14 mgkg-1,
i.p., MK) or Sal was then administered, and behavior was recorded for
a subsequent 1-h period (b). Results are mean±SEM. of N010–20
animals (a) and N010 animals (b). **P<0.01; ***P<0.001 vs. Sal (a)
or Sal+Sal (b) and ##P<0.01 and ###P<0.005 vs. MK+Sal (b), by
ANOVA followed by LSD post hoc test. ANOVA showed no overall
effect of F17141 on spontaneous activity (F4,5501.4, P00.23), but
a significant effect on MK-801-induced hyperactivity (F5,5305.6,
P00.00035)
Fig. 6 Reversion by F17141 and clozapine of social interaction
deficits induced by chronic NMDA-R blockade by MK-801 in mice.
A continuous 7-day treatment with MK-801 (0.02 mgkg-1h-1, s.c.)
induced a robust reduction of social interaction time (a, P00.0014,
by LSD post hoc test) and an increase in escape behavior (b, P09.7×
10-8, by LSD post hoc test) displayed by the resident mice compared to
saline controls. (a) F17141 (0.16–10 mgkg-1i.p.) acutely administered
30 min before the test dose dependently, and completely at the highest
doses, reversed the social interaction time deficits (a, ANOVA F5,570
4.0, P00.0033), and the escape behavior time increase (b, ANOVA
F5,5709.3, P01.6×10
-6). Clozapine (Cloz), used as an internal control,
administered acutely at the challenge dose of 1 mgkg-1i.p. 30 min
before the test, completely reversed social investigation deficits (a,
ANOVA F2,3808.85, P06.9×10
-4) and the exacerbated escape
behavior induced by MK-801 (b, ANOVA F2,38015.9, P09.3×10
-9).
Results are mean ± SEM of N08–15 animals. *P<0.05, **P<0.01,
and ***P<0.005 vs. Sal+Sal and #P<0.05, ##P<0.01, and ###P<0.005
vs. MK+Sal, by ANOVA followed by Fischer’s LSD post hoc test
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Clinical studies of D3 antagonists in schizophrenia
To date, two D3 receptor-selective compounds have reached
clinical proof-of-concept studies in schizophrenia, and the
results were reported. BP 897 was the first to be clinically
assessed in 2003 in patients with schizophrenia (Lecrubier
2003). It was a 4-week double-blind randomized placebo-
controlled study, enrolling 77 patients with schizophrenia.
Population sample was hospitalized schizophrenics with a
paranoid, disorganized, or undifferentiated subtype accord-
ing to DSM IV, presenting an acute episode of exacerbation;
52 patients were randomized to BP 897 (10 mg b.i.d.) and
25 to placebo. Plasma was collected at 8 and 28 days to
assay BP 897. A minimal score on positive symptoms
(PANSS subscore > 15) and on negative symptoms
(PANSS subscore>15) was required as well as a CGI>4.
After a 3–7-day placebo wash-out period, those with less
than 30 % improvement could be included. The primary
efficacy criterion was the difference between the PANSS
total score at baseline and after 4 weeks of treatment. Early
dropouts were 40 % in the BP897 group and 56 % in the
placebo group, mainly related to the absence of efficacy in
both groups; no adverse event emerged as frequent and/or
responsible for early dropout. In the intention-to-treat pop-
ulation, no difference was observed between BP 897 and
placebo on the primary efficacy criterion. In the per protocol
population treated for at least for 1 week, the mean differ-
ence of change between BP 897 (PANSS initial: 84.2±14.9,
final: 68.3±22, n044) and placebo (PANSS initial: 84±
15.4, final: 73.6±18.8, n017) was 10.75 (p00.024) when
adjusting for sex, center, and study duration. Plasma levels
were available in 33 patients treated with BP 897 and were
compared to the active BP897 plasma levels in rodent and
monkey models (~200 nM; see (Bezard et al. 2003): 11
patients had low BP 897 plasma levels (<50 nM at day
8 or 28), and their mean improvement on the PANSS was
7.1 versus 22.9 in the 22 other patients. Patients with the
highest plasma levels (>100 nM at days 8 and 28) show the
best improvement with a mean decrease from baseline of
26.9. No relevant adverse event was identified specially at
the extrapyramidal level. Although the efficacy of BP 897 in
acute or subacute schizophrenic patients was not demon-
strated in this study, probably related to a low dose not
reaching therapeutic levels, there was a strong trend toward
an antipsychotic effect dependent on plasma exposure, sup-
porting the hypothesis that a D3 receptor antagonist or
partial agonist could exhibit antipsychotic properties.
The second proof-of-concept clinical study assessed the
efficacy of ABT-925 and can be summarized as follows. In a
6-week, randomized, placebo controlled clinical study
(Redden et al. 2011), ABT-925 at doses of 50 and 150 mg
per day failed to produce antipsychotic effects, as measured
on the PANSS total score. However, a subsequent PET study
with [11C]-(+)-PHNO in healthy volunteers showed that, at
the doses used in the clinical study in patients suffering from
schizophrenia, probably less than 40 % of cerebral D3
receptors were occupied by ABT-925 (Graff-Guerrero et
al. 2010), suggesting that the doses used in the clinical study
were below the active therapeutic levels. Moreover, dose-
and time-dependent improvement by ABT-925 of cognitive
impairment associated with schizophrenia has been recently
reported (Abbs et al. 2012).
Hence, the present clinical experience with D3 antago-
nists in schizophrenia is inconclusive because the doses
tested are supposed to be insufficient to reach a clinically
active level in the two clinical studies reported so far. This
raises an important question to be addressed: which is the
minimal level of D3 receptor occupancy to be reached for
obtaining an antipsychotic effect? Indeed, there is no clinical
study linking D3 receptor occupancy and efficacy, so that
the question has to be answered on the basis of indirect
evidence. A comparison of the affinities of antipsychotic
drugs at recombinant D2 and D3 receptors indicates that
these compounds generally show some, but very limited,
preference for the D2 receptor (Sokoloff et al. 1992;
Sokoloff 2006). Hence, it can be assumed that 40–60 %
D3 receptor occupancy occurs during antipsychotic treat-
ments, resulting in 70–80 % D2 receptor occupancy, with
D2 receptor occupancy greater than 80 % resulting in
extrapyramidal side effect (Farde and Nordstrom 1993).
Nevertheless, a PET study in baboons has suggested that
D3 receptor occupancy by clozapine and haloperidol at
clinically active doses is probably lower than the above
figures (Girgis et al. 2011). However, since no safety con-
cern has been raised with D3 antagonists until now, the
doses to be tested in the clinics should be chosen to occupy
a large fraction of D3 receptors (>80 %) to maximize the
chance to get conclusive results, without compromising
tolerability. The clinical experience with BP 897 and ABT-
925 also indicates that the design of proof-of-concept stud-
ies with a novel mechanism should be supported by phar-
macodynamic studies, such as PET studies when adequate
tracers are available, in order to anticipate the clinically
active doses. Furthermore, in drug development with new
targets, the development of specific pharmacodynamic
translational markers should be encouraged even before
the initiation of a program.
Conclusions
The data collected so far indicate that the D3 receptor has the
ability to exert a control on glutamatergic activity, by acting
either directly on NMDA receptor signaling at glutamate
synapses on terminals of pyramidal cells in the nucleus
accumbens or indirectly through modulation of dopamine
120 Naunyn-Schmiedeberg's Arch Pharmacol (2013) 386:107–124
acting presynaptically on these cells in the prefrontal cortex.
This property is unique, insofar as it is not shared by other
dopamine receptor subtypes. Notably, the D2 receptor,
which is still considered as the main target for antipsychotic
drugs currently used in the clinics (Kapur and Mamo 2003),
is localized in both the cortical and subcortical areas. In the
striatum, its level of occupancy is correlated with the im-
provement of positive symptoms of schizophrenia. In the
cortex, however, blocking the D2 receptor, as do current anti-
psychotic drugs, disrupts the complex D1–D2 control over the
pyramidal cell/interneuron network and is certainly not optimal
to treat schizophrenia, particularly negative symptoms and
cognitive dysfunction. This is the reason why drug discovery
is presently oriented toward the development of drugs acting at
mGluR2/3 receptors or the glycine transporter (Kantrowitz and
Javitt 2012) to correct glutamate dysfunctions in the prefrontal
cortex. This approach needs to be consolidated by extensive
clinical studies, replicating the encouraging findings of proof-
of-concept studies. Also, evidence for long-term efficacy and
safety of these drugs is lacking so far.
Selective D3 receptor blockade appears as a promising
alternative to current D2/D3-based antipsychotics and a safe
mean to modulate glutamate in schizophrenia. This pharma-
cological intervention may be able to correct both positive
and negative symptoms of schizophrenia, as well as to
improve cognitive deficits associated with the disease.
Nevertheless, the D3 receptor hypothesis of schizophrenia
is still mainly based on indirect or preclinical evidence. So
far, it seems that the development of D3 compounds that
have reached the clinics has been discontinued for unclear
reasons except those related to the dose. The field of D3
drug discovery still appears active, and one can anticipate
that suitable drugs used at doses anticipated to reach the
target and occupy a large fraction of D3 receptors will be
available to obtain conclusive clinical results.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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